Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts

Llovet, 2003, Hepatocellular carcinoma, Lancet, 362, 1907, 10.1016/S0140-6736(03)14964-1 Voiculescu, 2008, Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic, J Gastrointestin Liver Dis, 17, 315 Hoshida, 2008, Gene expression in fixed tissues and outcome in hepatocellular carcinoma, N Engl J Med, 359, 1995, 10.1056/NEJMoa0804525 Hanahan, 2000, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J Clin Invest, 105, 1045, 10.1172/JCI9872 Bertolini, 2003, Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells, Cancer Res, 63, 4342 Man, 2002, Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water, Cancer Res, 62, 2731 Scripture, 2005, Modulation of cytochrome P450 activity: implications for cancer therapy, Lancet Oncol, 6, 780, 10.1016/S1470-2045(05)70388-0 Pasquier, 2010, Metronomic chemotherapy: new rationale for new directions, Nat Rev Clin Oncol, 7, 455, 10.1038/nrclinonc.2010.82 Coghlin, 2010, Current and emerging concepts in tumour metastasis, J Pathol, 222, 1, 10.1002/path.2727 Yao, 2009, Cancer stem cells and hepatocellular carcinoma, Cancer Biol Ther, 8, 1691, 10.4161/cbt.8.18.9843 Morrison, 2006, Asymmetric and symmetric stem-cell divisions in development and cancer, Nature, 441, 1068, 10.1038/nature04956 Morrison, 2008, Stem cells and niches: mechanisms that promote stem cell maintenance throughout life, Cell, 132, 598, 10.1016/j.cell.2008.01.038 Haraguchi, 2006, Characterization of a side population of cancer cells from human gastrointestinal system, Stem Cells, 24, 506, 10.1634/stemcells.2005-0282 Zhu, 2010, Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma, Int J Cancer, 126, 2067 Yang, 2008, Significance of CD90+ cancer stem cells in human liver cancer, Cancer Cell, 13, 153, 10.1016/j.ccr.2008.01.013 Haraguchi, 2010, CD13 is a therapeutic target in human liver cancer stem cells, J Clin Invest, 120, 3326, 10.1172/JCI42550 Yamashita, 2009, EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features, Gastroenterology, 136, 1012, 10.1053/j.gastro.2008.12.004 Folkins, 2007, Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors, Cancer Res, 67, 3560, 10.1158/0008-5472.CAN-06-4238 Colombo, 2011, Evidence of distinct tumour-initiating cells with different properties in primary human hepatocellular carcinoma, PLoS One, 6, e21369, 10.1371/journal.pone.0021369 Cicalese, 2009, The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells, Cell, 138, 1083, 10.1016/j.cell.2009.06.048 Liang, 2006, Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF, J Biol Chem, 281, 951, 10.1074/jbc.M508199200 Mancuso, 2009, Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses, Clin Cancer Res, 15, 267, 10.1158/1078-0432.CCR-08-0432 Martin-Padura, 2010, Sex-related efficiency in NSG mouse engraftment, Blood, 116, 2616, 10.1182/blood-2010-07-295584 Singh, 2010, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, Oncogene, 29, 4741, 10.1038/onc.2010.215 Manzotti, 1993, Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion, Clin Exp Metastasis, 11, 5, 10.1007/BF00880061 Tang, 2010, Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma, Neoplasia, 12, 264, 10.1593/neo.91872 Shao, 2010, Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma, Cancer, 116, 4590, 10.1002/cncr.25257 Ng, 2001, Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma, Am J Clin Pathol, 116, 838, 10.1309/FXNL-QTN1-94FH-AB3A Moon, 2003, Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?, Mod Pathol, 16, 552, 10.1097/01.MP.0000071841.17900.69 Poon, 2007, High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies, Ann Surg Oncol, 14, 1835, 10.1245/s10434-007-9366-z Poon, 2004, Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma, Br J Surg, 91, 1354, 10.1002/bjs.4594 Chiang, 2008, Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, 68, 6779, 10.1158/0008-5472.CAN-08-0742 Siegel, 2010, Sorafenib: where do we go from here?, Hepatology, 52, 360, 10.1002/hep.23633 Kerbel, 2004, The anti-angiogenic basis of metronomic chemotherapy, Nat Rev Cancer, 4, 423, 10.1038/nrc1369 Molloy, 2011, The prognostic significance of tumor cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients, Breast Cancer Res, 13, R61, 10.1186/bcr2898 Xu, 2011, Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy, Clin Cancer Res, 17, 3783, 10.1158/1078-0432.CCR-10-0498 Aguirre-Ghiso, 2007, Models, mechanisms and clinical evidence for cancer dormancy, Nat Rev Cancer, 7, 834, 10.1038/nrc2256 van Zijl, 2010, Hepatospheres: three dimensional cell cultures resemble physiological conditions of the liver, World J Hepatol, 2, 1, 10.4254/wjh.v2.i1.1 Liu, 2011, The power and the promise of liver cancer stem cell markers, Stem Cells Dev, 20, 2023, 10.1089/scd.2011.0012 Wang, 2010, Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway, Hepatology, 52, 528, 10.1002/hep.23692 Zeng, 2010, Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study, Eur J Cancer, 46, 1132, 10.1016/j.ejca.2010.01.014 Zielske, 2010, Loss of tumor-initiating cell activity in cyclophosphamide-treated breast xenografts, Transl Oncol, 3, 149, 10.1593/tlo.09307 Bauvois, 2006, Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects, Med Res Rev, 26, 88, 10.1002/med.20044 Inagaki, 2010, Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis, Biosci Trends, 4, 56 Haraguchi, 2010, CD13 is a therapeutic target in human liver cancer stem cells, J Clin Invest, 120, 3326, 10.1172/JCI42550